tenatoprazole and Peptic-Ulcer

tenatoprazole has been researched along with Peptic-Ulcer* in 3 studies

Reviews

2 review(s) available for tenatoprazole and Peptic-Ulcer

Article	Year
Tenatoprazole. Benatoprazole, TU 199. Drugs in R&D, 2002, Volume: 3, Issue:4 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Clinical Trials as Topic; Humans; Imidazoles; Omeprazole; Peptic Ulcer; Pyridines	2002
[Proton pump inhibitors: Tenatoprazole (TU-199)]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 2 Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Clinical Trials as Topic; Depression, Chemical; Gastric Acid; Humans; Imidazoles; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyridines	2002

Other Studies

1 other study(ies) available for tenatoprazole and Peptic-Ulcer

Article	Year
Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats. Methods and findings in experimental and clinical pharmacology, 1999, Volume: 21, Issue:2 We studied the effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal lesions in rats in comparison with those of omeprazole. TU-199 inhibited hog gastric H+, K(+)-ATPase activity and its potency was almost equal to that of omeprazole (IC50 = 6.2 and 4.2 microM, respectively). In vivo, TU-199 inhibited basal gastric acid secretion in pylorus-ligated rats in a dose-dependent manner (ED50 = 4.2 mg/kg p.o.). In gastric fistula rats. TU-199 (2.5 and 5 mg/kg i.d.) also inhibited gastric acid secretion stimulated by histamine, carbachol or tetragastrin. Furthermore, TU-199 prevented the formation of water-immersion restraint stress-, pylorus ligation- and indomethacin-induced gastric lesions, and mepirizole-induced duodenal ulcer in rats. These antisecretory and antiulcer effects of TU-199 were 2-4 times more potent than those of omeprazole. The results demonstrate that TU-199 potently inhibits the acid secretion and formation of ulcers in various experimental rat models via an inhibition of H+, K(+)-ATPase. These findings suggest that TU-199 may have a beneficial effect against peptic ulcer disease in humans. Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Drug Evaluation, Preclinical; Gastric Acid; Imidazoles; Male; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley	1999

Article

Year

Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats.

Methods and findings in experimental and clinical pharmacology, 1999, Volume: 21, Issue:2

We studied the effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal lesions in rats in comparison with those of omeprazole. TU-199 inhibited hog gastric H+, K(+)-ATPase activity and its potency was almost equal to that of omeprazole (IC50 = 6.2 and 4.2 microM, respectively). In vivo, TU-199 inhibited basal gastric acid secretion in pylorus-ligated rats in a dose-dependent manner (ED50 = 4.2 mg/kg p.o.). In gastric fistula rats. TU-199 (2.5 and 5 mg/kg i.d.) also inhibited gastric acid secretion stimulated by histamine, carbachol or tetragastrin. Furthermore, TU-199 prevented the formation of water-immersion restraint stress-, pylorus ligation- and indomethacin-induced gastric lesions, and mepirizole-induced duodenal ulcer in rats. These antisecretory and antiulcer effects of TU-199 were 2-4 times more potent than those of omeprazole. The results demonstrate that TU-199 potently inhibits the acid secretion and formation of ulcers in various experimental rat models via an inhibition of H+, K(+)-ATPase. These findings suggest that TU-199 may have a beneficial effect against peptic ulcer disease in humans.

Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Animals; Anti-Ulcer Agents; Drug Evaluation, Preclinical; Gastric Acid; Imidazoles; Male; Omeprazole; Peptic Ulcer; Proton Pump Inhibitors; Pyridines; Rats; Rats, Sprague-Dawley

1999